Goodpasture’s syndrome with absence of circulating anti-glomerular basement membrane antibodies: a case report by Rui Fernandes et al.
CASE REPORT Open Access
Goodpasture’s syndrome with absence of
circulating anti-glomerular basement
membrane antibodies: a case report
Rui Fernandes1*, Sara Freitas1, Pedro Cunha1,2, Gloria Alves1 and Jorge Cotter1,2
Abstract
Background: Goodpasture’s syndrome, a rare disease, is an organ-specific autoimmune disease mediated by
anti-glomerular basement membrane antibodies. Its pathology is characterized by crescentic glomerulonephritis
with linear immunofluorescent staining for immunoglobulin G on the glomerular basement membrane. Although
rare, a few cases with absence of circulating anti-glomerular membrane antibodies have been described.
Case presentation: The objective of this clinical case report is to describe and discuss a case of a 27-year-old white
man who was hospitalized with a 1-year history of weight loss and a 1-month history of hemoptysis, with
aggravation the day before, having developed dyspnea and cough in the previous 24 hours. An analytical study
showed normocytic normochromic anemia with a hemoglobin level of 7.2 g/dL and leukocytosis with normal
renal function and coagulation times. A blood transfusion was performed without complications. Chest computed
tomography revealed a reticulonodular infiltrate of both lungs. Bronchoscopy showed no apparent lesions. Sputum
cultures, rapid urine antigens for Legionella pneumophila and Streptococcus pneumoniae, studies for Influenza,
virologic markers and serologic studies for autoimmunity were all negative. At the end of the tenth
day his general state deteriorated with fatigue, hematuria, and in 3 days he developed aggravation of renal
function with recurrent hemoptysis and anemia. Immunosuppression with daily prednisolone 1 g administered
intravenously was initiated. An urgent bronchoscopy showed no lesions. A kidney biopsy showed fibrinoid necrosis
and cellular crescents. Immunofluorescence revealed a linear immunoglobulin G deposition compatible with
Goodpasture’s syndrome. Immunosuppressive therapy with daily cyclophosphamide 120 mg orally was added.
Subsequently he was transferred to a referral center at which 21 sessions of plasmapheresis and four sessions of
hemodialysis were performed with good response; he currently has no need of hemodialysis.
Conclusions: The absence of circulating anti-glomerular basement membrane antibodies in Goodpasture’s
syndrome adds complexity to the diagnosis creating an unusual setting in a rare disease. In our case a kidney
biopsy was essential for diagnosis and clinical approach. Studies have shown that early aggressive therapy leads to
an improved prognosis. Physicians should consider tissue diagnoses such as bronchoscopy and kidney biopsy in
pulmonary renal syndrome.
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Background
Goodpasture’s syndrome (GS) is a rare disease, identified
by Ernest Goodpasture [1]. It is an organ-specific auto-
immune disease that is mediated by anti-glomerular
basement membrane (anti-GBM) antibodies and its
pathology is characterized by crescentic glomeruloneph-
ritis with linear immunofluorescent staining for im-
munoglobulin G (IgG) on the glomerular basement
membrane (GBM). Its typical presentation is acute renal
failure due to rapidly progressive glomerulonephritis, as
well as pulmonary hemorrhage, which may be life-
threatening [2, 3]. It is estimated that the incidence of
GS is one case per million per year; however, it is re-
sponsible for acute renal failure in approximately 20 %
of all cases of rapidly progressive or crescentic glomer-
ulonephritis [4]. In the 1950s, Krakower and Greenspon
[5] identified the GBM as the antigen. The titer of circu-
lating autoantibodies is considered a measure of disease
severity correlating with renal outcomes [3].
The objective of this clinical case report is to describe
and discuss the case of a young man who presented with
acute pulmonary and renal involvement with atypical
features of GS.
Case presentation
A 27-year-old white man was hospitalized on 17 Sep-
tember 2014 with dyspnea and cough, which had started
the day before, and a 1-month history of small-volume
hemoptysis, which had aggravated in the last 24 hours.
He also reported a history of weight loss, corresponding
to 12 % of his corporal mass in the past year, but no
other accompanying symptoms. He reported a cigarette
smoking habit of 4 pack years, having occasionally
smoked recreational drugs (cannabis). He was also pro-
fessionally exposed to chemical toxics: thinners. There
was no previous history of renal or pulmonary disease.
No family disease was known and he had no other rele-
vant findings in his past medical history.
On examination at the time of admission he was
apyretic, his respiratory rate was 29 breaths/minute,
pulse rate was 118 beats/minute, and blood pressure
(BP) was 151/86 mmHg. We observed pallor of his skin.
Pulmonary auscultation revealed rales in his right
hemithorax and left base. A chest X-ray (CXR) showed
bilateral infiltrates (Fig. 1). An analytical study (Table 1)
showed a normocytic normochromic anemia with a
hemoglobin level of 7.2 g/dL and leukocytosis with
normal renal function and coagulation times. His
erythrocyte sedimentation rate was 34 mm/hour and
procalcitonin level was 0.309 ng/mL at the time of
admission. A urine analysis had no erythrocyturia or
eosinophiluria. His oxygen saturation was 96.8 % on
21 % oxygen with no signs of carbon dioxide (CO2)
retention and no electrolytic or acid-base changes.
Chest computed tomography (CT) revealed a reticulo-
nodular infiltrate of both lungs with extensive ground
glass appearance (Fig. 2).
He was initially treated with aminocaproic acid 3 g or-
ally every 8 hours and codeine 20 mg orally every 6
hours, having also completed 7 days of daily ceftriaxone
1 g administered intravenously and daily azithromycin
500 mg administered orally. Transfusion of two blood
units was performed with an increase in hemoglobin
count up to 8.9 g/dL (Table 1) without complications.
His serum urea and creatinine levels were 43 mg/dL and
0.78 mg/dL, respectively, at this time. A bronchoscopy
performed on the second day revealed hematic traces
with no other alterations or apparent lesions (Fig. 3). On
the fourth day of admission, he developed deterioration
of ventilatory parameters and of respiratory rate (32
breaths/minute) needing oxygen supplement via high
flow mask. Due to respiratory failure with a partial pres-
sure of oxygen (pO2) of 48.3 mmHg and an oxygen sat-
uration of 83.6 % on 100 % oxygen, he was transferred
to our intensive care unit (ICU), but did not require
mechanical ventilation. Sputum cultures were negative,
as were the rapid urine antigen tests for Legionella pneu-
mophila and Streptococcus pneumoniae. DNA analysis
for Mycobacterium tuberculosis was negative, as were
the studies for Influenza A, Influenza B, and Influenza
H1N1, and the serologic markers for human immuno-
deficiency virus, hepatitis C and hepatitis B. Direct and
indirect Coombs test were both negative. An echocar-
diogram was performed showing no significant findings.
Serologic tests for auto-antibodies (antinuclear anti-
bodies, anti-neutrophil cytoplasmic antibodies, and anti-
GBM antibodies) were negative.
After 5 days, he was transferred out of our ICU with a
good clinical and analytical evolution (Table 1). At the
end of the tenth day his general state deteriorated with
Fig. 1 Chest X-ray performed at admission. The X-ray displayed
bilateral pulmonary diffuse infiltrates
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fatigue and hematuria (327 erythrocytes/L) and in 3 days
he developed deterioration of renal function with a
serum creatinine level of 4.55 mg/dL and a serum urea
level of 189 mg/dL, with recurrence of hemoptysis and
anemia, showing a hemoglobin value of 6.1 g/dL
(Table 1). His pO2 value dropped to 55.5 mmHg with an
oxygen saturation of 89.4 % on 50 % oxygen. Immuno-
suppression with daily prednisolone 1g administered
intravenously was initiated. An urgent bronchoscopy
was repeated after new transfusion of three blood units,
showing no evidence of lesion again. His hemoglobin
level rose to 9.1 g/dL after the transfusion. A renal bi-
opsy was performed 24 hours after the bronchoscopy
and showed fibrinoid necrosis in glomeruli (19 glomeruli
were assessed) and cellular crescents in 26 % of glomeruli
(Fig. 4). Immunofluorescence revealed a linear deposition
of IgG, compatible with GS. Immunosuppressive therapy
with daily cyclophosphamide 120 mg orally was added.
Because of renal failure with a serum creatinine level of
5.13 mg/dL, he was transferred to a referral center where
he underwent 21 sessions of plasmapheresis and four ses-
sions of hemodialysis. Four weeks after initial presenta-
tion, his serum creatinine level was 1.8 mg/dL at the time
of his discharge from the reference center. Over the
course of 6 months, he completed treatment with
daily prednisolone 60 mg orally and daily cyclophos-
phamide 100 mg orally, maintaining regular follow-up
with out-patient nephrology, with currently no need
of hemodialysis. No further episodes of hematuria or
hemoptysis have been reported so far.
Discussion
GS typically occurs between the ages of 20 and 30 years
and between the ages of 60 and 70 years; the prevalence
of the disease is higher in men in the younger age group,
as in our case, whereas males and females are equally
Table 1 Analytical evolution for the period of hospitalization
Admission (17
September 2014)








Hemoglobin (g/dl) 7.2 8.9 6.1 9.1 12–16
Leucocytes (103/μL) 13.1 24.1 25.7 24.1 4.8–10.8
Neutrophils (103/μL) 9.9 21.9 23.6 22.3 1.8–7.7
Eosinophils (103/μL) 0.1 0 0 0 0.0–0.49
Lymphocytes (103/μL) 2.5 1.4 0.6 0.6 1.0–4.8
Platelets (103/μL) 364 477 449 221 150–350
Urea (mg/dL) 40.0 43.0 189 29 15–56
Creatinine (mg/dL) 0.97 0.78 4.55 5.13 0.6–1.3
C-reactive protein (mg/dl) 12.7 42.0 12.4 5.5 <3.0
Prothrombin time (seconds) 12.7 11.0 10.9 10.7 9.4–12.5
Activated partial thromboplastin
time (seconds)
28.6 22.2 24.2 26.3 25.1–35.6
Fig. 2 Chest computed tomography scan. The chest computed
tomography scan showed bilateral multilobular diffuse infiltrates
Fig. 3 Bronchoscopy performed on the second day after admission.
The examination revealed hematic traces throughout the
tracheobronchial tree with no evident active bleeding site or clots
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affected in the older age subgroup [3]. Although the
exact cause of GS is unknown, there are certain behav-
iors and environmental factors that may put people at
higher risk. Some factors such as viral respiratory infec-
tions, exposure to hydrocarbon fumes, metallic dust,
tobacco smoke or substances such as cocaine might be
involved [6] and were found in our patient assessment.
Symptoms may either start slowly, gradually affecting
the lungs and the kidneys, or they may progress rapidly,
becoming severe in a matter of days [7]. Constitutional
symptoms may precede or be concurrent with pulmon-
ary or renal manifestations. In general, there are sub-
stantial variations in the clinical manifestations of
patients with GS, with 60 to 80 % of the patients having
clinically apparent manifestations of pulmonary and
renal disease, 20 to 40 % having renal manifestations
alone, and less than 10 % having only pulmonary mani-
festations [6, 7]. Our case had a bimodal presentation
with an initial pulmonary involvement phase that
evolved to an almost asymptomatic state followed by a
fast pulmonary and renal degradation phase in a matter
of 3 days requiring a fast clinical approach.
Diagnosis of GS is made by detection of circulating
anti-GBM antibodies on solid phase, and a kidney biopsy
provides a definitive diagnosis with pathognomonic find-
ings on direct immunofluorescence of linear deposition
of immunoglobulin [8] that was evident in our case;
serologic assays for anti-GBM antibodies are valuable for
confirming the diagnosis and monitoring the adequacy
of therapy [3, 7]. Radioimmunoassays or enzyme-linked
immunosorbent assays (ELISAs) for anti-GBM anti-
bodies are highly sensitive (>95 %) and specific (>97 %);
immunoassay-based anti-GBM antibody kits showed
comparably good sensitivity [9]. In our case, blood
samples were processed shortly after collection in our
laboratory, which used a EliA™ System (Phadia, Freiburg,
Germany). The assay was performed twice on an Immu-
noCAP 250 instrument with a sensitivity of 96.4 % and a
specificity of 100 %.
At some time during the course of illness, one-third of
patients with GS have circulating anti-neutrophil cyto-
plasmic antibodies (ANCAs) in addition to anti-GBM
antibodies. In most cases, ANCAs are detectable several
months to years before the development of the disease
[3, 6, 7], which was not verified in our patient. In
patients with evidence of diffuse alveolar hemorrhage
and renal involvement, a kidney biopsy should be con-
sidered to identify the underlying cause. Percutaneous
kidney biopsy, which is subsequently analyzed by light
microscopy, immunofluorescence, and electron micros-
copy, is the preferred diagnostic procedure [8] and was
the cornerstone of our case, performed on time, con-
firming the diagnosis.
The three principles of therapy include: a) rapid removal
of circulating antibodies, primarily by plasmapheresis; b)
pharmacological immunosuppression to prevent further
production of antibodies; and c) removal of the offending
agents that may have triggered the antibody production.
Immunosuppressive therapy is required to inhibit anti-
body production and rebound hypersynthesis, which
may occur following discontinuation of plasma ex-
change [2, 7, 10]. High-dose corticosteroids and cyclo-
phosphamide represent the standard therapy. Initial
therapy includes cyclophosphamide 2 mg/kg orally,
adjusted to maintain a white blood cell count of ap-
proximately 5000 cells, and corticosteroids, which were
the choices in this clinical case.
Aggressive therapy with plasmapheresis, corticoste-
roids, and immunosuppressive agents has dramatically
improved the prognosis of GS [11]. Currently, the 5-year
survival rate exceeds 80 % and fewer than 30 % of pa-
tients require long-term dialysis, as was the case with
our patient. Serum creatinine levels greater than 4 mg/
dl, oliguria, and the presence of crescents in more than
50 % of glomeruli on renal biopsy predict a worse out-
come, with recovery being rare. Until today, no studies
on the best treatment of the syndrome have been per-
formed because of the rarity and the sometimes late
diagnosis of the syndrome [7]. A correct diagnosis is the
first important step to establish correct treatment. In a
published case series and in a randomized trial, plasma-
pheresis was shown to be beneficial in the treatment of
GS by the removal of anti-GBM antibodies [12]. Renal
transplantation has been used in end-stage renal disease
secondary to GS [13]; this was discussed with our pa-
tient, but fortunately he had recovery of renal function
obviating the need for this option. Although rare, the
absence of circulating anti-GBM has already been de-
scribed [14]. Of interest, our case is similar to the first
Fig. 4 Light microscopy on renal biopsy (hematoxylin eosin stain,
×400). Fibrinoid necrosis (black arrow) was seen in glomeruli
(19 glomeruli were examined), and there were cellular crescents
in 26 % of glomeruli
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case reported by Salama et al. [14]. The two cases have
sex, age group, exposure to risk factors (solvents), and
the time of development in common. However, presen-
tation was different; although our case emphasizes the
1-month history of hemoptysis with aggravation the day
before admission, Salama et al. refer solely to one
episode of mild hemoptysis [14]. Furthermore, our
patient improved after admission before final clinical de-
terioration started. In both cases, a renal biopsy was
diagnostic. Treatment was also comparable because both
patients underwent plasmapheresis and were adminis-
tered prednisolone orally and cyclophosphamide orally.
Evolution was sustainably favorable in the two cases: 8
weeks after initial presentation their patient’s serum cre-
atinine level was 2.5 mg/dL [14] as opposed to our pa-
tient who showed a serum creatinine level of 1.8 mg/dL
1 month after initial presentation. In our laboratory,
Western blot and biosensor analysis were not available
and, thus, further comparisons were not possible.
Conclusions
GS is a rare syndrome with many types of presentation
but it has to be considered in patients presenting with
pulmonary hemorrhage or anemia despite the absence of
anti-GBM antibodies. A kidney biopsy becomes essential
when confronted with this type of presentation, changes
in renal function, and clinical suspicion. Although no
studies have been performed for treatment approach,
with early diagnosis and therapy, survival rates have
increased.
The absence of anti-GBM antibodies adds complexity
to the diagnostic approach creating an unusual setting in
an already rare and complex disease.
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